NeOnc Technologies Holdings Inc

Home
United States
Calabasas, CA
NeOnc Technologies Holdings Inc

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from NeOnc Technologies Holdings Inc, Medical and health, 23975 Park Sorrento, Calabasas, CA.

05/18/2026

NeOnc is pleased to share that Maxim Group has initiated coverage with a Buy rating and a $20 price target in its analyst report!

We are proud to see continued recognition of our mission to advance innovative therapies for patients facing some of the most difficult-to-treat brain cancers.

Read the full report in our Investor highlight.

04/24/2026

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) continues to gain momentum.
BTIG has initiated coverage with a Buy rating and a $15.00 price target, led by analyst Thomas Shrader.

A strong vote of confidence as we advance innovative therapies for CNS cancers.

03/13/2026

NeOnc announced the appointment of David Choi, CPA, who will oversee accounting, financial reporting, internal controls, and corporate governance as the Company advances its clinical-stage programs targeting CNS cancers.

Mr. Choi previously held leadership roles at Blythe Global Advisors, Grant Thornton, and Ernst & Young, bringing extensive experience in SEC reporting, technical accounting, and SOX compliance.

🔗 Read the full release in our Investor highlight

03/04/2026

NeOnc Technologies (Nasdaq: NTHI) Reports Phase 1 Results for Oral NEO212 - Live Conference

NeOnc announced measurable anti-tumor activity in Phase 1, providing early clinical confirmation of NEO212’s therapeutic potential and supporting the Company’s progress into the Phase 2 segment of the trial.

With the recommended Phase 2 dose now established, the program moves forward into Phase 2 clinical development.

🎥 Watch the conference call from today:
https://www.webcaster5.com/Webcast/Page/3151/53708

Full press release in our Investor highlight!

02/27/2026

NeOnc Technologies Holdings Inc NTHI will host a live investor conference call and webcast on March 4, 2026 at 6:00 a.m. PT / 9:00 a.m. ET to present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial.

The discussion will include:
• Safety and toxicity findings
• Dose-escalation observations
• Pharmacokinetic data
• Planned regulatory next steps

NEO212 represents NeOnc’s proprietary bioconjugated temozolomide (TMZ) platform, designed to advance therapeutic options for patients with CNS malignancies.

📅 March 4, 2026
⏰ 6:00 a.m. PT / 9:00 a.m. ET
🔗 Live webcast: https://www.webcaster5.com/Webcast/Page/3151/53708

We look forward to sharing these important clinical updates with the investment community.

View the full release in our Investor highlight

02/24/2026

We’re thrilled to celebrate our CEO, , being featured in list of Top Entrepreneurs Going Into 2026 — a testament to visionary leadership and bold innovation shaping the future of biotech.

Under Amir’s leadership, NeOnc Technologies Holdings, Inc. continues to push boundaries in cancer research and therapeutic development — from advancing novel treatment platforms to driving strategic growth on the global stage. His commitment to bridging science, strategy, and impact has positioned NeOnc at the forefront of next-generation oncology innovation.

👏 Congratulations to Amir & NeOnc! Here’s to a year of breakthrough science, meaningful progress, and continued impact for patients worldwide.

Read the full article in our In The News highlight.

01/30/2026

NeOnc has secured a strategic PIPE investment led by a $10M commitment from Cinctive Capital Management, with total gross proceeds expected to reach ~$16M.

This investment reflects strong institutional confidence in NeOnc’s mission, science, and proprietary CNS delivery platforms. It supports the acceleration of clinical programs focused on bypassing the blood-brain barrier to treat CNS cancers.

Read the full press release in our Investor highlight!

01/02/2026

We are proud to share this video highlighting pediatric DIPG patients in China participating in investigator-sponsored studies evaluating NEO100-03, an investigational intranasal therapy developed by NeOnc Technologies.

These children were diagnosed with diffuse intrinsic pontine glioma (DIPG)—a rare and aggressive pediatric brain cancer with limited treatment options. Patients received NEO100-03 following prior standard therapies, including radiotherapy, and continue treatment under clinical supervision.

These stories highlight the urgent unmet medical need in pediatric brain cancer and reinforce the importance of continued clinical research into novel, non-invasive therapeutic approaches.

03/27/2025

We’re excited to announce that NeOnc Technologies Holdings, Inc. is now officially trading on the Nasdaq Global Market under the ticker symbol NTHI! Our team celebrated this momentous occasion by ringing the Opening Bell at Nasdaq MarketSite in Times Square. This marks a new chapter in our mission to develop advanced therapeutics for central nervous system disorders. We extend our deepest gratitude to our incredible team, partners, and supporters who have made this possible.
https://www.nasdaq.com/events/neonc-technologies-holdings-inc-rings-opening-bell?utm_source=chatgpt.com
Photo credit: Nasdaq, Inc./ Vanja Savic

02/25/2025

We’ve taken a significant step forward in our mission to advance neuro-oncology by filing a registration statement on Form S-1 with the SEC. As part of this process, we’ve also applied to list on NASDAQ under the ticker symbol NTHI and are awaiting final approval.

Stay tuned as we continue our journey toward becoming a publicly traded company!

02/20/2025

Treating brain diseases has always been a challenge due to the blood-brain barrier—but what if there were a more direct path?

NeOnc Technologies is pioneering a novel approach that leverages the olfactory nerve for targeted drug delivery to the brain. Our platform has the potential to bypass traditional barriers and directly transport therapeutics where they’re needed most.

Now in Phase II trials and granted FDA fast-track status, this breakthrough could open new possibilities for patients facing devastating neurological conditions.

Follow our journey as we push the boundaries of neuro-oncology and beyond!

Learn more: https://bit.ly/3ELeaSK

Address

23975 Park Sorrento
Calabasas, CA
91302

Telephone

+13109263314

Website

https://neonc.com/

Alerts

Be the first to know and let us send you an email when NeOnc Technologies Holdings Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to NeOnc Technologies Holdings Inc:

Shortcuts

Want your practice to be the top-listed Clinic in Calabasas?